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SARS-CoV-2 poses a major threat to the 
public health worldwide, as it causes a res-
piratory disease named COVID-19. Since 
the first case report in December 2019, 
a pandemic ensued with approximately 
one million deaths within the first nine 
months.[1] SARS-CoV-2 belongs to the 
beta-coronavirus genus. All coronaviruses 
have a lipid envelope with a capsid, which 
encapsulates the helical nucleocapsid with 
the RNA genome.[2] The most prominent 
viral envelope component is the spike 
glycoprotein (S), which interacts with the 
angiotensin-converting enzyme 2 (ACE2) 
on the surface of host cells and initiates 
virus entry, the first step of the SARS-
CoV-2 infection cycle.[1,3–5] Moreover, the 
polybasic cleavage site of S is found to 
play a crucial role in the binding between 
the virus and ACE2.[6] Numerous efforts 
have been devoted to development of vac-
cines that generate neutralizing antibodies 
toward S to block viral interaction with 
Search of new strategies for the inhibition of respiratory viruses is one of the 
urgent health challenges worldwide, as most of the current therapeutic agents and 
treatments are inefficient. Severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) has caused a pandemic and has taken lives of approximately two million 
people to date. Even though various vaccines are currently under development, 
virus, and especially its spike glycoprotein can mutate, which highlights a need 
for a broad-spectrum inhibitor. In this work, inhibition of SARS-CoV-2 by graphene 
platforms with precise dual sulfate/alkyl functionalities is investigated. A series 
of graphene derivatives with different lengths of aliphatic chains is synthesized 
and is investigated for their ability to inhibit SARS-CoV-2 and feline coronavirus. 
Graphene derivatives with long alkyl chains (>C9) inhibit coronavirus replication 
by virtue of disrupting viral envelope. The ability of these graphene platforms 
to rupture viruses is visualized by atomic force microscopy and cryogenic elec-
tron microscopy. A large concentration window (10 to 100-fold) where graphene 
platforms display strongly antiviral activity against native SARS-CoV-2 without 
significant toxicity against human cells is found. In this concentration range, the 
synthesized graphene platforms inhibit the infection of enveloped viruses effi-
ciently, opening new therapeutic and metaphylactic avenues against SARS-CoV-2.
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ACE2.[7–9] Similarly, the isolation and production of neutral-
izing antibodies targeting S promote the therapeutic treatment 
of SARS-CoV-2 infections, underscoring the importance of S as 
a target to block infection.[10–12] However, it is also noticed that 
SARS-CoV-2 can mutate and it is conceivable that only small 
mutation of S by could render previously neutralizing anti-
bodies ineffective.[13–15] Therefore, it is essential to consider a 
new target instead of the S to develop materials for a broad-
spectrum inhibition of coronaviruses.
Irreversible rupturing of the lipid viral envelope is a potential 
new approach for SARS-CoV-2 inhibition. Most of the surface-
active reagents, e.g., sodium dodecyl sulfonate, exhibit strong 
interactions with cellular membranes and can also rupture viral 
envelopes leading to inactivation of the virus, a so-called viru-
cidal compound. However, since they also act against the cel-
lular membranes, they are highly toxic and can only be used for 
ex vivo disinfection of surfaces and hands.[16–17] Hence, it is nec-
essary to find a less toxic alternative for SARS-CoV-2 inhibition. 
Earlier reports have pointed out that negatively charged amphi-
philic structures show broad-spectrum inhibitory activity via the 
interaction with the viral envelope, including but not limited to 
herpes simplex virus (HSV), respiratory syncytial virus, human 
metapneumovirus, hepatitis C virus, ZIKA virus, etc.[18–19]  
Surprisingly, in these studies with a fine tuning of charges and 
hydrophobicity, these compounds show low cytotoxicity but 
high virus inhibitory activity. The reason for such an observa-
tion could be due to the fast curing of membrane damages by 
self-repairing mechanisms.[20] Therefore, it is believed that the 
concept of envelope rupturing can be used to develop a robust 
SARS-CoV-2 inhibitor.[21]
Graphene, as a flexible 2D nanomaterial, is a promising candi-
date for the development of virus inhibitors due to the facilitated 
multivalent interactions at the functionalized interface.[22–23] 
Modified graphene nanoplatforms have shown significant inhibi-
tion of various pathogens due to their high binding affinity for 
bacteria and viruses.[24–30] Even though the possible mechanisms 
of the interactions between graphene derivatives and pathogens 
are still a controversial topic,[25,31] there are several suggested 
pathways for the antipathogenic action of these nanomaterials. 
Graphene materials are able to capture the pathogens by inter-
actions with specific antibodies or ligands,[32–33] electrostatic 
interactions,[34–36] trapping[37–38] or wrapping.[39–40] Furthermore, 
graphene sheets can destroy the pathogens by hydrophobic[23,41–42] 
or mechanical interactions.[43–44] The versatility of nanoplatforms 
has been shown by their inhibition of various viruses, exempli-
fied by designed inhibitors for HSV, African swine fever virus, 
alpha HSV, pseudorabies virus, and other viruses.[23,35,39,45] In 
previous studies, graphene-based compounds have been active 
against viruses mostly via a “binding and wrapping mechanism,” 
and have been virustatic inhibitors. Consequently, the virus is 
only temporarily inhibited from the interaction with host cells 
and the virus can escape from the inhibitor.[19]
Herein, we report the development of graphene-based viru-
cidal compounds that rupture the envelopes of coronaviruses 
thus inhibiting viral infection irreversibly. The surface of gra-
phene is functionalized with polyglycerol sulfate (PGS) and 
aliphatic chains of different length. In this study, we have 
investigated thoroughly how various sulfated graphene-based 
materials interact with the virions of feline coronavirus (FCoV) 
and SARS-CoV-2 to explore the potential of designing virucidal 
graphene-based inhibitors. A series of graphene platforms with 
PGS and alkyl amines of various chain lengths to surface of gra-
phene is synthesized and compared for their inhibitory effect 
on coronaviruses. Functionalized graphene platforms that bear 
alkyl chains shorter than 10 carbon atoms show moderate infec-
tion inhibition without significant toxicity for cells. However, 
materials with longer aliphatic chains (>9 carbon atoms) indi-
cate stronger inhibition and virion disruption of both coronavi-
ruses, authentic SARS-CoV-2 and FCoV, but also exhibit higher 
toxicity for eukaryotic cells. Our results demonstrate a key role 
of electrostatics, i.e., polyglycerol sulfate coverage for virus 
capturing and a strong correlation between the length of alkyl 
chains and virucidal activity of such functionalized graphene-
based materials against coronaviruses.
In order to construct a platform for synergistic electrostatic 
and hydrophobic interactions with SARS-CoV-2 (Figure 1a), gra-
phene derivatives with polyglycerol sulfate coverage (G-PGS) 
and dual alkyl amines/polyglycerol sulfate functionalities 
(G-PGS-Cx; x is the number of carbon atoms in aliphatic 
chains) were produced by our recently reported methods 
(Figure  1b).[23,46] First, triazine was attached to the surface of 
graphene, which formed platforms with dichlorotriazine func-
tional groups, and then polyglycerol with 5% amine functional 
groups was attached to the surface of these platforms. Next, 
the polyglycerol-covered graphene sheets were converted into 
their polysulfated analog, forming graphene-polyglycerol sul-
fate (G-PGS) (Figure S1, Supporting Information). Each step 
of functionalization was proven using X-ray photoelectron 
spectroscopy (XPS) due to the change in the elemental ratios 
both in survey and highly resolved C1s spectra (Figure S1b,c 
and Table S1, Supporting Information). Afterward, alkyl amines 
with various length of chains were attached to the triazine func-
tional groups of G-PGS and graphene materials with dual alkyl 
amine/polyglycerol sulfate functionalities (G-PGS-Cx) were 
produced (Figure  1b). The change in the ratio of CC/CO 
components in highly resolved C1s spectra during the function-
alization steps (Table S1, Supporting Information) proved suc-
cessful attachment of polyglycerol and alkyl amines to graphene 
surface. To explore the impact of the length of aliphatic chains 
on the antiviral activity of graphene platforms, alkyl amines 
with a different number of carbon atoms (x = 6, 9, 10, 11, and 
12) were conjugated to the surface of G-PGS. The charge of the 
various graphene derivatives was not affected due to the attach-
ment of alkyl chains (Table  1). According to the atomic force 
microscopy (AFM) measurements (Figure 1c–e), conjugation of 
long alkyl moieties to the surface of G-PGS did not change lat-
eral size of sheets, however G-PGS-Cx height was significantly 
increased (10.5  nm for G-PGS-C12; 6.1  nm for G-PGS-C6) in 
comparison with G-PGS (3.8 nm), according to the height and 
lateral size histograms of corresponding materials (Figure S2, 
Supporting Information).
The cytotoxicity of the functionalized graphene sheets 
against lung epithelial cells (A549), lung bronchial epithe-
lial cells (HBE) and kidney Vero E6 cells was investigated by 
assessing the cells viability with the colorimetric assay Cell 
Counting Kit-8 (CCK-8). While samples with long aliphatic 
chains (≥10) reduced the cell viability at 50  µg mL−1 consider-
ably, the samples with shorter aliphatic chains (<10) did not 
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show significant toxicity against the investigated cells lines 
(Table 1). It is presumed to be caused by the different interac-
tions between the functionalized graphene platforms with dif-
ferent alkyl chains and the cell membranes. The functionalized 
graphene platforms with long aliphatic chains (≥10) could pen-
etrate the cellular membrane to induce cell death, while their 
counterparts with shorter alkyl chains were not able to diffuse 
into the membrane of the host cell. Therefore, it is reasonable 
to presume that long aliphatic chains are needed for efficient 
inactivation of viral particles (Table  1 and Figures S3 and S4: 
Supporting Information). These outcomes are in line with our 
earlier findings on graphene/pathogen interfaces, where elec-
trostatic interactions were capturing factor and hydrophobic 
interactions were rapturing factor.[23,47–48]
Figure 1. a) Schematic representation of intended interactions between G-PGS-C11 and SARS-CoV-2. While negatively charged polyglycerol sulfate 
interact with the positively charged domains of S on the surface of SARS-CoV-2, aliphatic chains penetrate into its membrane and disintegrate the virus. 
b) Schematic representation of the synthesis of G-PGS-Cx. Synthesis of G-PGS derivatives with i) short (C6, C9) and ii) long aliphatic chains (C10, C11, 
and C12). G-PGS, DMF, C6H13NH2/C9H19NH2/C10H21NH2/C11H23NH2/C12H25NH2, triethylamine, 25–60 °C, 24 h. c–e) AFM images with enlarged parts 
showing typical size and height of graphene sheets, and highly resolved f–h) XPS spectra for G-PGS-C6, G-PGS, and G-PGS-C12, respectively. Scale 
bars correspond to 100 nm.
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Next, we studied inhibitory effects of the functionalized 
graphene platforms with FCoV, a coronavirus strain infecting 
cats. Though the S of FCoV and SARS-CoV-2 are slightly 
different, their envelope structures are similar, qualifying 
FCoV to be a surrogate to SARS-CoV-2 for inhibition studies. 
Plaque reduction assay showed dose-dependent inhibition 
efficiency for the incubated compounds (Figure  2a). In line 
with cellular interaction studies, the functionalized graphene 
platforms with longer aliphatic chains showed stronger virus 
inhibition than their counterparts with shorter alkyl chains. 
The transition domain for effective virus inhibition was the 
chain length from C9 to C10, the half maximal inhibitory con-
centration (IC50) values of G-PGS-C9 (749.4 ± 107.8 µg mL−1) 
and G-PGS-C10 (9.8 ± 10.2 µg mL−1) (Table 1 and Figure 2b). 
G-PGS-C11 was the most effective inhibitor and showed 
potent inhibition toward FCoV with an IC50 value of 
6.3 ± 1.2 µg mL−1, highlighting the necessity of long aliphatic 
chains for virus inhibition. IC50 values of G-PGS-C12 toward 
Figure 2. a) Cell viability versus plaque reduction (FCoV) curves of the functionalized graphene platforms at different concentrations. b) Comparison 
between CC50 (Vero E6 cells) with the IC50 (FCoV) values for the compounds. c) Immunofluorescent images for the FCoV-infected cells in the presence 
of G-PGS, G-PGS-C9 and G-PGS-C11 at 10 µg mL−1. Scale bar: 100 µm. The images for other compounds are shown in the Supporting Information. 
d) Counting of infected cells by FCoV in the presence of G-PGS, G-PGS-C9, and G-PGS-C11 at 100 µg mL−1. e) Titration of virions in the medium from 
the pre- and post-infection studies. Values are expressed as mean ± SD, n = 4. ****p < 0.001 from student’s t-test.
Table 1. Zeta-potential, cytotoxicity, and IC50 values of graphene platforms against both FCoV and SARS-CoV-2.
Sample Zeta-potential mV CC50Vero E6 [µg mL−1] IC50FCoV [µg mL−1] IC50SARS-CoV-2 [µg mL−1]
G-PGS −46 ± 5 >1000 >1000 >1000
G-PGS-C6 −46 ± 5 >1000 >1000 >1000
G-PGS-C9 −49 ± 7 >1000 749.4 ± 107.8 339.7 ± 128.8
G-PGS-C10 −56 ± 11 63.4 ± 35.8 9.8 ± 10.2 29.1 ± 12.2
G-PGS-C11 −54 ± 8 68.9 ± 26.4 6.3 ± 1.2 0.8 ± 0.3
G-PGS-C12 −56 ± 10 100.1 ± 40.2 85.2 ± 50.9 22.9 ± 7.4
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FCoV were lower than for G-PGS-C11 (85.2 ± 50.9 µg mL−1). 
Therefore, material with the aliphatic chain length consisting 
of 11 carbon atoms showed the optimum values for the virus 
inhibition.
We further investigated the ability of the compounds to pro-
tect the cells from the infection by FCoV. The cells were first 
incubated with the compounds for 1 h and then infected with 
FCoV at a multiplicity of infection (MOI) of 0.1, a procedure 
we refer to as pre-infection treatment. After 24 h of infec-
tion, the cells were stained by anti-FCoV antibodies to deter-
mine infection (Figure  2c–e). The number of infectious virus 
in the medium was studied by plaque reduction assays and 
expressed as plaque-forming units per mL (PFU mL−1) to quan-
titate virus replication (Figure  2e). Without treatment, robust 
infection was observed by FCoV and the virus titer reached 
≈2 × 105 PFU mL−1. Pre-treatment of cells with the compounds 
reduced FCoV infection. G-PGS-C11 nearly abolished the infec-
tion in the pretreatment test. There were no infected cells 
observed, at our detection limit, and only 10 PFU mL−1 of FCoV 
were detected in the medium, corresponding to an inhibi-
tory effect higher than 99.99%. These results indicated that 
G-PGS-C11 could be a potent prophylactic agent to prevent 
coronavirus infections.
In order to study the inhibition of virus replication by func-
tionalized graphene sheets after internalization into the cells, 
cells were first infected and then incubated with the graphene 
derivatives, which we refer to as post-infection treatment. Infec-
tion efficiency and virus replication were studied by antibody 
staining and plaque assay. In this case G-PGS-C6 and G-PGS-C9 
showed poor inhibition. Even though the number of infected 
cells decreased slightly, the virus titer in the medium was at the 
comparable level as the control experiment. However, G-PGS-C11 
showed clear inhibition in the post-infection treatment study. 
Only a few infected cells, which were probably infected before 
treatment with compounds, were observed. Virus replication 
was reduced to ≈100 PFU mL−1, corresponding to an inhibitory 
effect higher than 99.9%. The cells also survived from the treat-
ment, as the number of cells was not decreased, indicated by 
Hoechst 32 253 staining (Figure 2e and Figure S5: Supporting 
Information). The activity of G-PGS-C11 in the post-infection 
treatment study indicated that it could be a therapeutic agent 
toward coronavirus infection.
The inhibition of virus by the functionalized graphene plat-
forms was further investigated by a virucidal assay. It should be 
mentioned that most inhibitors act through a virustatic mecha-
nism. They inhibit virus infection through competitive binding 
of the virus to its receptor.[12,49–50] In this case, virions are only 
blocked from entry into host cells instead of being completely 
deactivated. Upon dilution of the inhibitor below its IC50, the 
virions may be released from the inhibitors and are able to 
start the infection again.[18–19] To ensure the final deactivation 
of virions, virucidal compounds that damage virions irrevers-
ibly should be developed, especially for the highly infectious 
SARS-CoV-2. To test the virucidal potential of the compounds, 
the FCoV virions (>106 PFU) were first incubated with the 
compounds a 1000 times higher concentration than their IC50 
values for 1 h. After dilution to a concentration 10-times lower 
than their IC50, the number of active virions was determined 
by plaque assay (Figure  3a). Samples, which showed a clear 
reduction of active virions even below the IC50 values, were 
considered as virucidal compounds.
Similar to the results of the plaque reduction assays, a clear 
transition from virustatic to virucidal was observed at C9-C10. 
While samples with aliphatic chains <10 (G-PGS, G-PGS-C6, 
and G-PGS-C9) were virustatic, the platforms with aliphatic 
chains ≥ 10 (G-PGS-C10, G-PGS-C11, and G-PGS-C12) were 
virucidal. G-PGS-C11 was considered as the best material with 
two orders of magnitudes of virus titer reduction. The results 
of the plaque reduction assay and the virucidal assays showed 
that aliphatic chains more than 9 carbon atoms on the sur-
face of graphene were necessary for virus membrane rupture 
(Figure 3b). G-PGS-C11 showed the best activities for both virus 
inhibition and virucidality, indicating that in our system, ali-
phatic chain with 11 carbon atoms was the optimal.
To reveal the virucidality of the compounds and investigate 
the influence of functionalized graphene platforms on viruses 
under native (hydrated) conditions, we used cryogenic trans-
mission electron microscopy (cryo-EM). Purified FCoV virions 
were incubated with G-PGS-C6 (virustatic) and G-PGS-C11 
(virucidal) for 1 h and fixed by 2.5% formaldehyde. The sam-
ples were then cryofixated by plunge freezing and microscopi-
cally analyzed in a 200  kV TEM under low-dose conditions 
(Figure  3c). Pristine FCoV showed the typical morphology of 
coronavirus. The virions had a diameter of about 100 nm with 
visible S anchored on the surface of the envelope. We were not 
able to recognize the functionalized graphene platforms, prob-
ably because the ultra-thin 2D material tends to generate a very 
low contrast. However, the virions incubated with G-PGS-C6 
still exhibited the typical morphology of coronavirus with intact 
S on the surface of the envelope (Figure 3c). The observations 
suggested that the virustatic compound (G-PGS-C6) interacted 
with the virions without damaging them, at least no morpho-
logical changes were visible on the virions after incubation. In 
case of incubation with G-PGS-C11, the virions underwent mor-
phological alterations (Figure  3c). Most noticeably, the virions 
disintegrated by rupturing the envelope and depleting the S. 
The observation correlates well with the results of virucidal 
assay where virions were inactivated upon interactions with 
G-PGS-C11.
To study the interactions of FCoV with graphene sheets fur-
ther, the samples were analyzed by AFM in liquid conditions 
(Figure 3d and Figure S6: Supporting Information). AFM con-
firmed that the lateral dimensions of virions were in the same 
size range as in Cryo-EM. S could be identified clearly in the 
topographic images of FCoV virions alone, as well as in case 
of FCoV virions that were incubated with G-PGS-C6. Moreover, 
G-PGS-C6 sheets interacting with the surface of FCoV virion 
could be observed (Figure 3d and Figure S6: Supporting Infor-
mation). However, in case of G-PGS-C11 the virions were not 
intact anymore, and they lost their spherical morphology and 
were disrupted due to the interactions with graphene sheets 
that covered the virions (Figure 3d and Figure S6: Supporting 
Information). Taken together, the results confirmed our hypoth-
esis that the negatively charged PGS bound electrostatically to 
the positive patches on the S,[51] and aliphatic chains interacted 
with the viral envelope (Figures 1a and 3b). The lipid interaction 
enabled the rupture of the viral envelope and consequently the 
inactivation of the virus. The 2D flexible structure of graphene 
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Figure 3. a) Virucidal assay for the functionalized graphene platforms. Values are expressed as mean ± SD, n = 4. b) Schematic illustration of virus 
rupturing by G-PGS-C11. c) Cryo-EM images for pristine FCoV virions and FCoV virions incubated with G-PGS-C6 and G-PGS-C11 for 1 h. d) AFM images 
of FCoV virion with clear S on its surface; FCoV virions incubated with G-PGS-C6 and G-PGS-C11 for 1 h.
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further facilitated multivalent interactions with the virus and 
enhanced both virus binding and incapacitation.[43]
The half maximal cytotoxic concentration (CC50) and FCoV 
IC50 for G-PGS-C11 were 42.6  ± 30.1 and 4.7  ± 0.7  µg mL−1, 
respectively. The range between these two concentrations rep-
resents a therapeutic window that could be considered for 
virus inhibition and incapacitation without serious damaging 
of host cells. As shown on Figure  2b, in both pre- and post-
infection treatment studies, the treatment by G-PGS-C11 at 
10 µg mL−1 eliminates FCoV infection without showing cellular 
toxicity. The difference between virus inhibition and cellular 
toxicity may be explained by the surface curvature of biosys-
tems. A virus is only 100 nm in diameter, while a cell normally 
exhibits a surface of 10  µm. Therefore, the membrane curva-
ture and strain are higher in the virus compared to the cells. 
The self-repairing machinery also enables the cells to tolerate 
membrane damage and to restore the membrane.[20] The virus 
particles mainly contain genetic information but no enzymes or 
other structures, thereby lacking the ability to repair membrane 
damage by virucidal inhibitors.
Finally, the inhibitory effect of the functionalized graphene 
platforms on authentic SARS-CoV-2 was studied using a plaque 
reduction assay (Figure  4a,b). Similar to the results of FCoV, 
the compounds with long aliphatic chains showed the strongest 
inhibition. Alkyl chains with more than 9 carbon atoms were 
necessary for the inhibition of SARS-CoV-2. G-PGS-C11 showed 
the strongest inhibition with an IC50 of 0.8  ± 0.3  µg mL−1, 
with a selectivity index (ratio of CC50 to IC50) of 86. Although 
G-PGS-C11 showed toxicity at high concentrations, the potent 
inhibition of SARS-CoV-2 at doses much lower than its CC50 
value may allow safe antiviral treatment with this inhibitor. 
For example, G-PGS-C11 showed clear virus inhibition at 
50  µg mL−1, a concentration where this compound did not 
show significant cellular toxicity. As shown in the image of the 
plaque reduction assays of Figure 4a, at this concentration the 
base cell layer remained intact, indicating no cellular toxicity. 
For G-PGS-C11, the virions remained inhibited upon dilution, 
indicating that the virions were inhibited irreversibly. There-
fore, G-PGS-C11 was considered virucidal to SARS-CoV-2, due 
to interactions with viral envelope. The other functionalized 
graphene platforms (G-PGS, G-PGS-C6, and G-PGS-C9) were 
virustatic instead of virucidal (Figure 4c).
We successfully synthesized graphene platforms with 
defined dual polyglycerol sulfate/aliphatic chains function-
alities for SARS-CoV-2 binding and disintegration. In contrast 
with previously reported virustatic graphene-based inhibitors, 
the synthesized inhibitors in this study were found to be viru-
cidal. Virions bound to the functionalized graphene sheets 
by multivalent electrostatic interactions with the negatively 
charged PGS were disintegrated by the alkyl chains. Disrup-
tion of coronavirus envelopes occurred with elongation of ali-
phatic chains from G-PGS-C9 to G-PGS-C10 and showed the 
strongest inhibition and virucidality against feline coronavirus 
with G-PGS-C11. Therefore, alkyl chains should be long enough 
to exert efficient disintegration of the viral envelope. To rupture 
the envelop of the virus, the negatively charged PGS branches 
first interacted with the positively charged patches of the virion, 
then the aliphatic chains ruptured the membrane of the viral 
envelop. Graphene acted as a 2D platform to facilitate the inter-
actions with virus particles. G-PGS-C11 displayed the most effi-
cient antiviral properties against authentic SARS-CoV-2 without 
showing significant toxicity against eukaryotic host cells. The 
Figure 4. a) Typical plaque images for SARS-CoV-2 treated by the functionalized graphene platforms at 50 µg mL−1. b) Plaque reduction curves for 
SARS-CoV-2 in the presence of the functionalized graphene platforms at different concentrations. c) Virucidal assay for the functionalized graphene 
platforms. Values are expressed as mean ± SD, n = 4.
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observed post-treated effect and selectivity index of 86 opens 
the door for potential therapeutic applications.
Experimental Section
Plaque Reduction Assays: The compounds were 10-fold diluted in 
Dulbecco’s Modified Eagle’s Medium (DMEM) and incubated with 
FCoV-containing solutions with ≈100 PFU for 1 h at 37 °C. Afterward, the 
number of active virions was determined by plating the virus/compound 
mixture on a confluent monolayer of CRFK cells. Virus adsorption was 
allowed for 1 h before the supernatant was aspirated and replaced by a 
semi-solid overlay of 1.3% methylcellulose (viscosity 400 cP). The overlay 
was removed after 48 h; cells were fixed with 4% formalin and stained 
with FCoV-specific antibodies (primary antibody: mouse anti-FCoV, 
Bio-Rad, cat# MCA2194; secondary antibody: Goat anti-Mouse IgG Alexa 
Fluor 488, Invitrogen, cat# A32723) to visualize plaques. The plaque 
reduction ratio was determined as following
Plaque reduction % 1
Plaque number sample
Plaque number virus control






 ×  (1)
Virucidal Assay: The functionalized graphene platforms (1  mg mL−1) 
were incubated with FCoV suspension containing ≈1 × 105 PFU for 1 h 
at 37 °C. Afterward, the mixture was diluted in DMEM medium 10-foldly 
5 times to an endpoint of no active virions. The number of active virions 
was determined by plaque assay and virus titers were calculated back by 
the respective dilutions.
Plaque Reduction Assay and Virucidal Assay on SARS-CoV-2: SARS-CoV-2 
München (SARS-CoV2M; BetaCoV/Germany/BavPat1/2020) was 
propagated in Vero E6 cells and titrated via plaque assay.[52] The plaque 
reduction assay and virucidal assay were performed in the same procedure 
as for FCoV, except that the plaques were stained by 0.75% crystal violet. 
The experiment was performed within the BSL3 lab in the Institute of 
Virology, Department of Veterinary Medicine at the Freie Universität Berlin.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
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